VISTASEAL
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- VISTASEAL
- Generic name
- HUMAN FIBRINOGEN, HUMAN THROMBIN
- Manufacturer
- GRIFOLS USA, LLC
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- a8708417-2f74-4dfa-b6f9-ef88f902e0fc
- SPL ID
- 54f6ba29-974e-400a-80d4-13c351229916
- Version
- 14
- Effective date
- 2025-08-13
- Source export date
- 2026-11-13
- Source partition
- 10
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:15:33
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125640 | derived:openfda.application_number |
| application number | BLA125640 | openfda.application_number | |
| brand name | VISTASEAL | openfda.brand_name | |
| generic name | HUMAN FIBRINOGEN, HUMAN THROMBIN | openfda.generic_name | |
| manufacturer name | GRIFOLS USA, LLC | openfda.manufacturer_name | |
| ndc | package | 61953-0013-1 | openfda.package_ndc |
| ndc | package | 61953-0012-1 | openfda.package_ndc |
| ndc | package | 61953-0011-1 | openfda.package_ndc |
| ndc | package | 61953-0014-1 | openfda.package_ndc |
| ndc | product | 61953-0011 | openfda.product_ndc |
| ndc | product | 61953-0014 | openfda.product_ndc |
| ndc | product | 61953-0013 | openfda.product_ndc |
| ndc | product | 61953-0012 | openfda.product_ndc |
| ndc11 | package | 61953001101 | derived:openfda.package_ndc |
| ndc11 | package | 61953001301 | derived:openfda.package_ndc |
| ndc11 | package | 61953001201 | derived:openfda.package_ndc |
| ndc11 | package | 61953001401 | derived:openfda.package_ndc |
| rxcui | 2264608 | openfda.rxcui | |
| rxcui | 2264603 | openfda.rxcui | |
| rxcui | 2264606 | openfda.rxcui | |
| rxcui | 2264609 | openfda.rxcui | |
| rxcui | 2264604 | openfda.rxcui | |
| rxcui | 2264607 | openfda.rxcui | |
| rxcui | 2264371 | openfda.rxcui | |
| rxcui | 2264366 | openfda.rxcui | |
| spl id | 54f6ba29-974e-400a-80d4-13c351229916 | id | |
| spl set id | a8708417-2f74-4dfa-b6f9-ef88f902e0fc | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Thromboembolic events may occur if VISTASEAL is administered intravascularly. ( 5.1 ) Hypersensitivity reactions can occur. ( 5.2 ) May carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.3 ) 5.1 Thrombosis Life-threatening thromboembolic complications may occur if VISTASEAL is administered intravascularly. 5.2 Hypersensitivity Allergic-type hypersensitivity reactions are possible. Signs of hypersensitivity reactions include hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If these symptoms occur, discontinue the administration of VISTASEAL immediately. Treat the reaction accordingly. 5.3 Transmissible Infectious Agents Because VISTASEAL is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and theoretically, the Creutzfeldt-Jakob (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. All suspected infections related to this product should be reported by the physician or other healthcare provider to Grifols Therapeutics LLC at 1-800-520-2807. The physician should discuss the risks and benefits of the use of VISTASEAL with the patient. [see Patient Counseling Information ( 17 )]
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (reported in >1% of patients) were procedural pain, and nausea. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Grifols Therapeutics LLC at 1-800-520-2807 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety data described in this section reflect exposure to VISTASEAL in four clinical studies. A total of 591 patients (489 adults and 102 pediatric) received VISTASEAL for vascular (Study 1), parenchymal (Study 2 and Study 4), or soft tissue (Study 3 and Study 4) surgery . [see Clinical Studies ( 14 )] The most frequently occurring adverse reactions are shown in Tables below. In the VISTASEAL group in these 4 trials, 11% of trial patients experienced one or more adverse reactions, and 7% of control patients experienced one or more adverse reactions. Table 4. Adverse Reactions Occurring in >1% of Patients in Study 1, 2, and 3 and Study 4 (Combined) Preferred Term N = 591 n (%) Procedural pain 11 (2) Nausea 6 (1) Table 5. Adverse Reactions Occurring in >1% of Patients in Study 1 Preferred Term N = 168 n (%) Procedural pain 4 (2) Nausea 2 (1) Pyrexia (fever) 2 (1) Vascular graft complication 2 (1) Parvovirus B19 test positive 2 (1) Urinary retention (Unable to empty the bladder completely) 2 (1) Table 6. Adverse Reactions Occurring in >1% of Patients in Study 2 Preferred Term N = 163 n (%) Postprocedural bile leak 2 (1) Procedural pain 2 (1) Pulmonary embolism (Blood clot in the lungs) 2 (1) Deep vein thrombosis (Blood clot that forms in a vein deep) 2 (1) Table 7. Adverse Reactions Occurring in >1% of Patients in Study 3 Preferred Term N = 169 n (%) Nausea 4 (2) Procedural pain 4 (2) Pruritus (Itching) 4 (2) Anemia (Low red blood cells) 2 (1) Leukocytosis (Increased white blood cells) 2 (1) Ileus (Decreased or absent movement of the stomach or intestine) 2 (1) Alanine aminotransferase increased 2 (1) Aspartate aminotransferase increased 2 (1) Hypocalcemia (Low serum calcium) 2 (1) Hypokalemia (Low serum potassium) 2 (1) Hyponatremia (Low serum sodium) 2 (1) Prothrombin time prolonged (Increased bleeding time) 2 (1) Headache 2 (1) Insomnia 2 (1) Hypertension 2 (1) Additionally, in the pediatric clinical study (Study 4) conducted to assess safety and efficacy of VISTASEAL compared to EVICEL (human fibrin sealant), one adverse reaction (procedural pain) occurred in one patient (1%) who received VISTASEAL. [see Pediatric Use ( 8.4 ) and Clinical Studies [ 14 ]] 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of VISTASEAL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. General disorders and administration site conditions : adhesions
adverse reactions table
<table ID="SPLSERV-e10ad086-bb62-4f08-bc24-18cdcbc62ff9" border="1" cellpadding="4" cellspacing="0" styleCode="Noautorules" width="60%"><caption>Table 4. Adverse Reactions Occurring in >1% of Patients in Study 1, 2, and 3 and Study 4 (Combined) </caption><colgroup><col/><col/></colgroup><tbody><tr><td align="center" styleCode="Botrule Lrule Rrule Toprule"><content styleCode="bold">Preferred Term</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule"><content styleCode="bold">N = 591 </content><content styleCode="bold">n (%)</content></td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Procedural pain</td><td align="center" styleCode="Botrule Lrule Rrule Toprule">11 (2) </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Nausea</td><td align="center" styleCode="Botrule Lrule Rrule Toprule">6 (1) </td></tr></tbody></table>
adverse reactions table
<table border="1" cellpadding="4" cellspacing="0" styleCode="Noautorules" width="60%"><caption>Table 5. Adverse Reactions Occurring in >1% of Patients in Study 1</caption><colgroup><col/><col/></colgroup><tbody><tr><td align="center" styleCode="Botrule Lrule Rrule Toprule"><content styleCode="bold">Preferred Term</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule"><content styleCode="bold">N = 168 </content><content styleCode="bold">n (%)</content></td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule" valign="top">Procedural pain </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">4 (2) </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule" valign="top"> Nausea </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 2 (1) </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule" valign="top"> Pyrexia (fever) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">2 (1) </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule" valign="top"> Vascular graft complication </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 2 (1) </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule" valign="top"> Parvovirus B19 test positive </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 2 (1) </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule" valign="top"> Urinary retention (Unable to empty the bladder completely) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 2 (1) </td></tr></tbody></table>
adverse reactions table
<table border="1" cellpadding="4" cellspacing="0" styleCode="Noautorules" width="60%"><caption>Table 6. Adverse Reactions Occurring in >1% of Patients in Study 2</caption><colgroup><col/><col/></colgroup><tbody><tr><td align="center" styleCode="Botrule Lrule Rrule Toprule"><content styleCode="bold">Preferred Term</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule"><content styleCode="bold">N = 163 </content><content styleCode="bold">n (%)</content></td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule" valign="top"> Postprocedural bile leak </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 2 (1) </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule" valign="top"> Procedural pain </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 2 (1) </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule" valign="top"> Pulmonary embolism (Blood clot in the lungs) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 2 (1) </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule" valign="top"> Deep vein thrombosis (Blood clot that forms in a vein deep) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 2 (1) </td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.